Cardiac Toxicity of Macrolide Antibiotics | CMAC

Cardiac Toxicity of Macrolide Antibiotics

Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(4):262-266

​ Galeeva Zh.A., Zyryanov S.K.
macrolides QT interval ventricular arrhythmias
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2015; 17(4):262-266

Abstract

This review describes known mechanisms, possible causes of cardiac toxicity of macrolides antibiotics and the incidence of this adverse effect.

Zhanna A. Galeeva

Pirogov Russian National Research Medical University, Moscow, Russia

Sergey K. Zyryanov

Pirogov Russian National Research Medical University, Moscow, Russia

  • 1. Waldo A.L., Camm A.J., deRuyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7-12
  • 2. Hondeghem L.M. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability). Novartis Found Symp 2005; 266:235-44.
  • 3. Hondeghem L.M. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur J Pharmacol 2008; 584:1-9.
  • 4. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation 2001; 103:2004-13.
  • 5. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350:1013-22.
  • 6. Резник А.В., Федоров В.В., Розенштраух Л.В. Ионные каналы и токи в кардиомиоцитах. Кардиология 2006; 1:4-18.
  • 7. Schram G., Pourrier M., Melnyk P., Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function Circ Res 2002; 90:939-50.
  • 8. Malik M., Camm A.J. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 2001; 24: 323-51.
  • 9. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med 1989; 111:549-51.
  • 10. Rubart M., Pressler M.L., Pride H.P., Zipes D.P. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993; 88:1832-44.
  • 11. Daleau P., Lessard E., Groleau M.F., Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995; 91:3010-16.
  • 12. Antzelevitch C., Sun Z.Q., Zhang Z.Q., Yan G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28:1836-48.
  • 13. Itoh H., Sakaguchi T., Ding W.G., et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced longQT syndrome. Circ Arrhythm Electrophysiol 2009; 2:511-23.
  • 14. Walter A., Volberg B.J., Koci W.S., Jing L., Jun Z. Blockade of Human Cardiac Potassium Channel Human Ether-ago-go-Related Gene (HERG) by Macrolide Antibiotics. J Pharmacol Exp Ther July 1, 2002302:320-327; published online July 1, 2002, doi:10.1124/jpet.302.1.320.
  • 15. Donger C., Denjoy I., Berthet M., et al. KVLQT1 C-terminal missense mutation causes a forme fruste longQT syndrome. Circulation 1997; 96:2778-81.
  • 16. Napolitano C., Schwartz P.J., Brown A.M, et al. Evidence for a cardiac ion channel mutation underlying druginduced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11:691-6.
  • 17. Paulussen A.D.C., Gilissen R.A.H.J, Armstrong M., et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004; 82:182-8.
  • 18. Lehtonen A., Fodstad H., Laitinen-Forsblom P., Toivonen L., Kontula K., Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007; 4:603-7.
  • 19. Yang P., Kanki H., Drolet B., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105:1943-8.
  • 20. Ponsonnaille J., Citron B., Richard A., Trolese J.F., Chaperon A., Barret B., Gras H. Electrophysiological study of pro-arrhythmogenic effects of erythromycin [in French]. Arch Mal Coeur Vaiss 1988; 81:1001-8.
  • 21. Mishra A., Friedman H.S., Sinha A.K. The effects of erythromycin on the electrocardiogram. Chest 1999; 115:983-6.
  • 22. Kdesh A., McPherson C.A., Yaylali Y., Yasick D., Bradley K., Manthous C.A. Effect of erythromycin on myocardial repolarization in patients with communityacquired pneumonia. South Med J 1999; 92:1178-82.
  • 23. Guo D., Cai Y., Chai D., et al. The cardiotoxicity of macrolides: a systematic review. Pharmazie 2010; 65(9): 631-40.
  • 24. Westphal J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000; 50:285-95.
  • 25. Shi J., Montay G., Bhargava V.O. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005; 44:915-34.
  • 26. Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23:106-31.
  • 27. Zhou S.F., Xue C.C., Yu X.Q., Li C., Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P4503A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29:687-710.
  • 28. Damkier P., Hansen L.L., Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999; 48:829-38.
  • 29. Granowitz E.V., Tabor K.J., Kirchhoffer J.B. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol 2000; 23:1433-5.
  • 30. Choi Y.H., Yu A.M. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014; 20:793-807.
  • 31. Thelen K., Dressman J.B. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61:541-58.
  • 32. Eberl S., Renner B., Neubert A., Reisig M., Bachmakov I., Konig J., et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007; 46:1039- 49.
  • 33. Hughes J., Crowe A. Inhibition of P-glycoproteinmediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci 2010; 113:315-24.
  • 34. Gomes T., Mamdani M.M., Juurlink D.N. Macrolideinduced digoxin toxicity: a population-based study. Clin Pharmacol Ther 2009; 86:383-6.
  • 35. Goldschmidt N., Azaz-Livshits T., Gotsman, N.R., BenYehuda A., Muszkat M. Compound cardiac toxicity of oral erythromycin and verapamil. Ann Pharmacother 2001; 35:1396-9.
  • 36. Li C., Kim C.S., Yang J.Y., Park Y.J., Choi J.S. Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats. Eur J Drug Metab Pharmacokinet 2008; 33:231-6.
  • 37. Tschida S.J., Guay D.R., Straka R.J., Hoey L.L., Johanning R., Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996; 16:663-674.
  • 38. Lee K.L., Jim M-H., Tang S.C., Tai Y-T. QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 1998; 104:395-6.
  • 39. Ray W.A., Murray K.T., Hall K., Arbogast P.G., Stein C.M. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1861-90.
  • 40. Svanstrom H., Pasternak B., Hvid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368:1704-12.
  • 41. Mosholder A.D, Mathew J., Alexander J.J., Smith H., Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013; 368:1665-8.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared